Portal de Periódicos da CAPES

Seroconversion rates following COVID-19 vaccination among patients with cancer

2021; Cell Press; Volume: 39; Issue: 8 Linguagem: Inglês

10.1016/j.ccell.2021.06.002

1878-3686

Astha Thakkar, Jesus D. Gonzalez‐Lugo, Niyati Goradia, Radhika Gali, Lauren C. Shapiro, Kith Pradhan, Shafia Rahman, So Yeon Kim, Brian Ko, R. Alejandro Sica, Noah Kornblum, Lizamarie Bachier‐Rodriguez, Margaret McCort, Sanjay Goel, Román Pérez-Soler, Stuart H. Packer, Joseph A. Sparano, Benjamin A. Gartrell, Della Makower, D. Goldstein, Lucia R. Wolgast, Amit Verma, Balázs Halmos,

COVID-19 Clinical Research Studies

As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.